Medmira (MIR) AI Stock Analysis

• Market Cap: C$48.84M
• Dividend Yield: N/A
• Average Volume (3M): 94.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: -41.70%
• EPS Growth: -35.42%
• Country: CA
• Employees: 65
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 697,666,140
• 10 Day Avg. Volume: 79,718
• 30 Day Avg. Volume: 94,909
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.07 ▼(-4.29% Downside)

Medmira's overall stock score is primarily impacted by its poor financial performance, characterized by negative profitability and weak balance sheet. Technical analysis and valuation also contribute to the low score, with bearish momentum and unattractive valuation metrics.

Positive Factors

Market Demand

Growing demand for rapid diagnostic tests in emerging markets supports long-term revenue potential, aligning with global health trends.

Product Offering

Proprietary rapid test technologies offer a competitive edge by providing reliable, easy-to-use solutions, enhancing market position.

Revenue Streams

Diverse revenue streams from sales, licensing, and partnerships enhance financial stability and market reach, supporting growth.

Negative Factors

Financial Performance

Negative profitability and declining revenues indicate structural financial challenges, impacting long-term sustainability.

Balance Sheet Health

Negative equity and high financial risk limit financial flexibility, posing long-term challenges to operational stability.

Cash Flow Challenges

Persistent negative cash flows highlight cash generation issues, constraining investment and growth opportunities.

Medmira Business Overview & Revenue Model

Company Description

Medmira Inc. (MIR) is a Canadian biotechnology company primarily focused on the development and commercialization of rapid diagnostic tests for various infectious diseases. The company operates in the healthcare sector, specializing in point-of-care testing solutions that enable quick and accurate diagnosis of conditions such as HIV, Hepatitis, and other sexually transmitted infections. Medmira's core product offerings include its proprietary rapid test technologies, which are designed to provide reliable results with minimal equipment and training, catering to both clinical and non-clinical settings worldwide.

How the Company Makes Money

Medmira generates revenue through the sale of its rapid diagnostic tests to healthcare providers, laboratories, and distributors across multiple regions. The company has established key revenue streams that include direct sales of its products, licensing agreements for its technologies, and partnerships with other healthcare organizations to expand its market reach. Additionally, Medmira benefits from contracts with government agencies and non-governmental organizations (NGOs) that require diagnostic testing solutions in various public health initiatives. The company's focus on innovation and the increasing demand for rapid diagnostic solutions in emerging markets further contribute to its financial performance.

Medmira Financial Statement Overview

Summary

Medmira is facing significant financial challenges across all major statements. The company is struggling with profitability, financial stability, and cash generation. High leverage and negative equity raise concerns about solvency, while negative margins and cash flows highlight operational inefficiencies. Significant improvements are needed to enhance the financial health and sustainability of the company.

Income Statement

Medmira's income statement reveals significant challenges. The company is experiencing declining revenue growth with a negative gross profit margin, indicating cost inefficiencies in production. Net profit margin is negative, suggesting sustained losses, and both EBIT and EBITDA margins are negative, highlighting operational difficulties.

Balance Sheet

The balance sheet shows high financial leverage with a negative stockholders' equity, indicating potential solvency issues. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, reflecting financial instability. These factors suggest a high-risk financial position.

Cash Flow

Cash flow analysis shows negative free cash flow, indicating the company is not generating sufficient cash to cover capital expenditures. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting revenue into cash. However, the cash flow from financing activities is positive, indicating dependency on external funding to support operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	240.51K	240.51K	412.57K	432.53K	952.13K	2.14M
Gross Profit	-117.30K	-990.25K	226.49K	-434.91K	304.03K	1.72M
EBITDA	-3.13M	-3.13M	-2.13M	-1.58M	-1.07M	185.30K
Net Income	-4.52M	-4.52M	-3.33M	-2.68M	-1.83M	-675.80K
Balance Sheet
Total Assets	3.68M	3.68M	6.07M	3.65M	3.83M	3.89M
Cash, Cash Equivalents and Short-Term Investments	14.91K	14.91K	2.10M	13.18K	33.46K	-2.30M
Total Debt	10.71M	10.71M	9.56M	9.27M	8.30M	11.54M
Total Liabilities	26.24M	26.24M	24.11M	18.68M	16.19M	19.61M
Stockholders Equity	-22.56M	-22.56M	-18.04M	-15.03M	-12.36M	-15.72M
Cash Flow
Free Cash Flow	-3.15M	-3.15M	-3.68M	-1.27M	-1.95M	-541.19K
Operating Cash Flow	-3.15M	-3.15M	-2.94M	-1.27M	-1.88M	-504.64K
Investing Cash Flow	-7.47K	-7.47K	-742.53K	-1.27K	-69.72K	-36.55K
Financing Cash Flow	1.07M	1.07M	5.77M	1.25M	1.99M	139.32K

Medmira Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.51 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MIR.

Medmira Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	57 Neutral	C$47.71M	22.90	7.07%	―	5.29%	-29.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBX	49 Neutral	C$31.97M	-14.56	-8.01%	―	-26.81%	-161.24%
MIR	41 Neutral	C$48.84M	-10.77	―	―	-41.70%	-35.42%
SVA	33 Underperform	C$45.45M	-2.71	―	―	―	54.38%
DTC	30 Underperform	C$36.67M	-10.17	―	―	―	72.92%

Medmira Corporate Events

MedMira Launches Clinical Trial for HIV/Syphilis Self-Test in Canada

MedMira has launched a clinical trial for its Multiplo® TP/HIV self-test in Canada, marking a significant step in addressing the rising cases of HIV and syphilis in the country. The trial, supported by Health Canada and funded by the Canadian Institutes of Health Research, aims to bring the self-test to communities in need, bypassing traditional regulatory steps. This initiative is expected to empower individuals with privacy and control over their health, potentially reducing the spread of these infections by providing immediate results and facilitating access to care.

MedMira Reports Q2 FY2025 Results, Advances in STI and HIV Testing

MedMira Inc. reported its second quarter financial results for FY2025, highlighting significant advancements in product launches and regulatory progress. The company introduced its Health Canada approved Multiplo® TP/HIV and Reveal® Rapid HIV Test in Canada, generating strong demand and working towards expanding its STI product portfolio. MedMira is also pursuing regulatory approvals in the U.S. for its Reveal® G4 HIV-1/2 rapid test and is in discussions to accelerate the commercialization of its MiROQ technology. Despite increased operating expenses due to clinical trials, these developments position MedMira for enhanced market access and potential growth.